.After raising $170 million back in February, metabolic disease-focused BioAge Labs has submitted to debut on the general public market.The Eli Lilly-partnered biotech plan to specify on the Nasdaq under the symbolic representation "BIOA," according to documents filed along with the Securities as well as Substitution Percentage. The business has not publicly discussed an expected monetary amount for the offering.The clinical-stage business boasts lead prospect azelaprag, a by mouth delivered tiny molecule slated to get in stage 2 testing in combination along with semaglutide-- marketed through Novo Nordisk under brand name Wegovy for fat loss-- in the first fifty percent of next year. Semaglutide is actually also sold as Ozempic and also Rybelsus by Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is actually created to mix well along with GLP-1 drugs, improving weight management while preserving muscular tissue mass. The investigational medication was located to be well-tolerated among 265 people around 8 stage 1 trials, depending on to BioAge.Recently, BioAge achieved the assistance of Lilly to manage a test combining azelaprag along with the Significant Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetes mellitus as Mounjaro and also Zepbound for fat burning. The partners are actually presently conducting a stage 2 test of azelaprag and also tirzepatide, with topline end results expected in the 3rd fourth of 2025.The biotech is actually additionally organizing a the hormone insulin sensitivity proof-of-concept trial determining azelaprag as a monotherapy in the initial one-half of next year to sustain potential evidence growth. On top of that, the provider intends to ask the FDA for approval in the second one-half of 2025 to launch individual testing for an NLRP3 prevention targeting metabolic diseases and neuroinflammation.BioAge's expected move to the general public market adheres to a slight uptick in organized biotech IPOs coming from Bicara Therapies and also Zenas Biopharma. Zooming out, the current IPO garden is a "blended photo," along with top notch providers still debuting on the public markets, simply in lessened amounts, depending on to PitchBook.